Objective: ATAD1 encodes Thorase, a mediator of a-amino-3-hydroxy-5-methylisoxazole-4-proprionate (AMPA) receptor recycling; in this work, we characterized the phenotype resulting from ATAD1 mutations and developed a targeted therapy in both mice and humans.
receptor density, excitatory neurotransmission, excitotoxicity, and neuronal death. ATAD1 knockout mice have seizures and die between postnatal days 19 and 25. Given the similarity between mice and humans lacking functional Thorase, we designed a targeted therapeutic approach using the AMPAR antagonist, perampanel, 8, 9 and found that it improves behavior and survival in mice and eliminates seizures and improves tone in patients.
METHODS Further information can be found in the supplemental methods at Neurology.org/ng.
Study design. The objective of this study was to first identify the etiology of the subjects' hypertonia and seizure disorder using exome sequencing and autozygosity mapping. Once the ATAD1 mutation was identified, the next objective was to evaluate the efficacy of the AMPA receptor antagonist, perampanel, in both a mouse model of ATAD1-associated disease and human ATAD1 patients. For mouse behavioral and imaging studies, a group size of 6 was chosen so that given an SD of 10%, an 18% difference in the mean values between the 2 groups could be detected with a power of 80%. The sample size for the human studies was determined by the number of available patients and family members. The human therapeutic trial was an open-label single-center compassionate use trial in the 2 affected patients. Because of technical limitations, the study was not randomized or blinded. Clinical improvement in the patients was measured using the Functional Status Score, a validated pediatric outcome measurement, 10 see supplemental methods for more details.
Standard protocol approvals, registrations, and patient consents. Animal experiments were performed in compliance with the regulations of the Animal Ethical Committee of the Johns Hopkins University Animal Use and Care Committee. For human studies, written informed consent was obtained for the trial and for publications of photos and videos. The study was approved by the Children's Hospital of Philadelphia Institutional Review Board. figure 1 ) was symptomatic at birth and presented to our center at age 9 months. He was nonresponsive to tactile, visual, and auditory stimuli with no spontaneous movement and extreme hypertonia. EEG at 9 months showed hypsarrhythmia, a chaotic interictal pattern suggestive of severe brain dysfunction. He did not demonstrate infantile spasms as his extreme hypertonia precluded almost all movement. Brain MRI at 2 months of life was normal, but repeat at 9 months showed marked interval reduction in cerebral volume. Prior investigations (table 1) were unrevealing. The second patient was the proband's 2-month old male cousin (individual IV-3, figure 1 ). He also Figure 1 Subjects' pedigree demonstrates multiple affected individuals in a highly consanguineous family
The proband is patient IV-6; his cousin who was subsequently evaluated and treated is patient IV-3. The ATAD1 variant, p.E276X, was identified by wholeexome sequencing and tracked with disease in all available family members (1 represents the normal allele and 2 represents the p.E276X allele). See also figure e-1.
had a history of hypertonia and clinical seizures at birth. On first evaluation at our center at 2.5 months of age, he had little spontaneous movement and was extremely stiff (video 1). EEG at presentation while on phenobarbital demonstrated a background lacking normal mixture of frequencies and poorly formed sharps but no seizures. Brain MRI was unremarkable. Exome sequencing of patient IV-6 revealed no mutations in known disease-causing genes. However, a homozygous nonsense variant of unknown significance in ATAD1 (c.826 G.T, p.E276X) was reported (figure e-1A). His parents each carried 1 copy of the change. The variant was classified as having a potential relationship to a disease phenotype. There are no previous reports of ATAD1 mutations in humans; however, mice harboring mutations in ATAD1 have frequent seizures, hypertonia, and early death. 7 Compound heterozygote variants of unknown significance were also found in SZT2, which causes autosomal recessive epileptic encephalopathy type 18; however, the variants did not segregate in his affected sister (IV-5) and he did not fit this phenotype (supplemental results).
SNP analysis confirmed that the family was consanguineous (table e-1). Patient IV-6 was found to have a de novo 1.25 Mb duplication of 17p13.3 (for more details, see supplemental results). Overlapping duplications have been reported with variable phenotypes including mild dysmorphic features, learning disability, hypotonia, autism spectrum disorder, and mild brain abnormalities. 11 This duplication was not present in affected individuals IV-3 or IV-5. Furthermore, given the extreme hypertonia and early respiratory failure seen in individual IV-6, we did not feel that this could fully explain his phenotype.
Homozygosity mapping revealed that the patient (IV-6), his deceased affected sister (IV-5), and affected cousin (IV-3) shared only one region of homozygosity (ROH) that was not shared with any unaffected relative (III 1-4 and IV-1, 2, and 7). This 6.5 Mb shared ROH (chr10:83,619,940-90,095,915, hg19 coordinates) contained 28 protein-coding genes, 14 of which are associated with a known disease phenotype (tables e-2 and e-3). ATAD1 is located in this shared ROH, while SZT2, the other candidate gene identified through exome sequencing, is not. Molecular analysis confirmed that all affected family members were homozygous for the p.E276X variant, while unaffected family members were not (figure 1). Multipoint genetic linkage analysis of 8 SNPs as markers in this region demonstrated a logarithm of the odds (LOD) score of 3.7 (table e-4), while the LOD score calculated directly using only the ATAD1 p.E276X variant was 3.5. An LOD score $3.3 has been shown to correspond to a genomewide significance level of ,0.05.
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The effect of the p.E276X variant on ATAD1 expression was investigated in lymphoblastoid cells derived from the patient and an unaffected control. ATAD1 messenger RNA expression was decreased by 78% in p.E276X cells. This degree of reduction is consistent with nonsense-mediated decay, 13 as noted by the absence of Thorase protein on Western blotting (figure e-1B). Investigation of ATAD1 variation in control populations revealed that in the Exome Table 1 Initial examination features and prior evaluations for patient IV-6 and patient IV Aggregation Consortium (exac.broadinstitute.org/ gene/ENSG00000138138) database, only 3 loss-offunction variants were observed in the gene, while the expected number of loss-of-function variants is 14.9. This suggests selection against loss-of-function mutations in ATAD1.
Evaluation of perampanel as a therapeutic approach.
Given that the p.E276X variant tracked with disease, decreased ATAD1 expression, and that ATAD1 knockout mice died of seizures, we concluded that this mutation was likely pathogenic. ATAD1 mutations increase AMPA receptor-mediated excitatory signaling due to impaired receptor recycling. 7 Considering this mechanism of disease, we hypothesized that perampanel, 14, 15 a noncompetitive AMPAR antagonist could have therapeutic benefit. Therefore, we investigated the efficacy of perampanel in ATAD1 2/2 mice. Perampanel dosing in mice was based on prior studies 8 and a dose escalation study (figure e-2).
Perampanel response in mice. Ex vivo brain MRI of ATAD1 2/2 mice (figure 2A figure 2B ). Loss of ATAD1 was also associated with increased T2-signal intensity throughout the brain, which is indicative of brain pathology with increased fluid content ( figure 2C ). Perampanel improved wholeslice signal intensity in ATAD1 2/2 animals by 30.3% (95% confidence interval 11.3%-59.5%); further analysis of individual brain regions revealed improvement of signal intensity in the thalamus and striatum ( figure 2D) .
On open-field activity testing, ATAD1 2/2 mice showed both an abnormal activity pattern as compared to wild-type mice (figure 3, A-H) and decreased spontaneous movements as measured by the distance traveled and the total rest time (figure 3, I and J). Perampanel corrected these behavioral deficits, while phenobarbital, an antiepileptic that targets g-aminobutyric acid (GABA) receptors rather than AMPA receptors, did not. ATAD1 2/2 mice showed no difference in rearing activity or average speed as compared to wild-type littermates (figure e-3). Extensive daily observations revealed that ATAD1 2/2 mice would have seizures on the day that they died. Video recording revealed that 5 of 5 vehicletreated, as compared to zero of 5 perampanel-treated, ATAD1 2/2 mice demonstrated seizures (video 2). Finally, perampanel significantly prolonged average survival in ATAD1 2/2 mice by 115% (mean of 20 vs 43 days), while phenobarbital did not significantly increase survival ( figure 3K ). These results demonstrate the efficacy of targeted AMPAR blockade by perampanel in mice with impaired AMPAR endocytosis due to mutations in ATAD1.
Perampanel response in humans. Given the efficacy of perampanel in mice, we next considered a therapeutic trial in patients with ATAD1 mutations. Perampanel was recently approved by the FDA for the treatment of seizures and demonstrated minimal off-target toxicity in human studies 15 ; we obtained permission for off-label compassionate use for treatment of affected individuals. Patient IV-6 was started on perampanel at 16 months of age; at this time, he had severe brain atrophy on MRI (figure 4A), hypertonia, absent cranial nerve reflexes, no spontaneous respiratory drive, and hypsarrhythmia on EEG. Within 8 days of starting perampanel, his tone improved and he developed a pupillary response to light. He continued to show dosedependent neurologic improvement until his neurologic status plateaued at a dose of approximately 0.5 mg/kg/d (figures 4C, e-4, e-5). He also had resolution of hypsarrhythmia on EEG (figure 4, D-G). He was weaned off all nonperampanel antiepileptics, which included phenobarbital (dose at start of trial 6 mg/kg/d), topiramate (dose at start of trial 6 mg/kg/d), and valium (dose at start of trial 0.9 mg/kg/d). Despite therapy, he continued to have severe neurologic deficits and worsening hydrocephalus requiring endoscopic third ventriculostomy.
In light of the clinical improvement seen in the proband, patient IV-3 was started on perampanel at 2.5 months of age. Given his young age, his neurologic function was more intact as compared to his cousin's at the start of therapy. While he was profoundly hypertonic, he had normal cranial nerve reflexes and respiratory drive. After starting perampanel, he had rapid improvement in tone and normalization of his EEG (video 1). Like his cousin, he was weaned from his other seizure medications including phenobarbital (dose at start of trial of 2.5 mg/kg/d). Repeat brain MRI at 9 months of age showed no parenchymal volume loss while on perampanel ( figure 4B ), a finding that is dramatically different from what was seen in the proband at age 9 months (figure 4A, middle MRIs). Despite these Figure 4 Perampanel improves hypertonicity, prevents seizures, and slows neurodegeneration but cannot normalize neurologic function in patients with ATAD1 mutations (A) Photographs and brain MRIs of the proband, individual IV-6. Initial brain MRI at 2 months showed normal parenchyma, but subsequent studies at 9 and 21 months showed progressive volume loss and hydrocephalus. (B) Photographs and brain MRI of patient IV-3. Brain MRI at 2 months of age was normal. Perampanel was started at 2.5 months of age and follow-up MRI at 9 months of age showed no changes (unlike the progressive neurodegeneration seen in untreated patient IV-6 over the same age range, panel A). markers of improvement, he developed respiratory failure requiring intubation. However, his limited function was better as compared to his cousin who was untreated at the same age: he maintained all brain stem reflexes, sleep/wake cycles, the ability to withdraw and vocalize to pain, and spontaneous movements of all extremities (figure 4C, and supplemental information). Functional improvement was also measured using the functional status score, a validated pediatric outcome measurement. 10 This outcome assesses 6 functional domains (mental status, sensory, communication, motor, feeding, and respiratory function), each on a scale from 1 (normal) to 5 (severely impaired), and a composite score is calculated. Fully functioning children receive a score of 6, while maximal impairment is assigned a score of 30. Over the course of therapy, patient IV-6 had a score improvement from 29 to 24 (figure e-4, A and B). Patient IV-4 began the trial with a functional status score of 19 and showed an initial improvement to a low score of 17. However, his overall functional score worsened despite therapy at 3-4 months of age due to his respiratory failure (figure e-4, C and D). At the end of the therapeutic trial, his functional status score plateaued at 23, as compared to his untreated cousin's score of 29 at the same age. This suggests that perampanel may improve functional outcomes but cannot completely prevent progression of disease. DISCUSSION We describe a disorder of AMPAR recycling caused by mutations in ATAD1, a gene not previously known to cause human disease. Affected patients demonstrate hypertonicity, seizures, and early death. Targeted therapy with perampanel alters the pathogenic mechanism and provides benefit in both mouse models and patients.
This case series demonstrates the power of combining genomic testing and variant analysis using animal models. In addition, we confirm that combining detection of variants in novel genes and an understanding of disease mechanisms can inform care of an individual. This effort has achieved a clinical diagnosis, improved understanding of AMPAR function, and suggested therapeutic options.
As the first report of ATAD1-induced human disease, this work builds on previous observations that mutations that interrupt normal synaptic transmission can cause seizures. 16, 17 Postsynaptic receptor recycling is a known pathogenic mechanism in epilepsy; for example, mutations in KIF5A reduce postsynaptic expression of inhibitory GABA A receptors, reducing total inhibition and leading to seizures and encephalopathy. 18 Unlike KIF5A mutations that decrease total inhibition, ATAD1 mutations increase the population of excitatory postsynaptic receptors. Ultimately, either mechanism can disrupt the delicate balance between inhibitory and excitatory signaling and induce seizures.
While this study highlights the promise of personalized medicine, there are limitations to this work. ATAD1 mutations have been identified in only one family. Typically, a gene is not considered as disease causing until it has been observed in 2 families. In this case, we have accumulated multiple lines of evidence supporting the pathogenicity of ATAD. First, the variant tracked within the family and LOD scores calculated both by a multipoint analysis method and the ATAD1 variant itself showed statistically significant linkage. Second, we functionally showed loss of ATAD1 protein in patient lymphocytes. Third, it is a stop-gain mutation and is absent from multiple control populations, and multiple computation programs predict its pathogenicity. Lastly, the ATAD1 p.E276X variant is classified as pathogenic when applying the recently published ACMG variant analysis guidelines criteria for classification. 5 As this is a new, ultra-rare disorder, there is limited understanding of its natural history. This makes evaluation of perampanel efficacy difficult. For example, patient IV-3 required tracheostomy despite treatment with perampanel. It is possible that therapy was initiated too late in the natural progression of the disease or at too low of a dose to prevent this outcome. Nonetheless, he had better preservation of neurologic function than the few known untreated family members at the same age. The superior functional status scores in our patient initiated at a younger age could be related to drug effect or due to interindividual variation. Furthermore, we used an open-label therapeutic intervention strategy. This raises the possibility that treating physicians could be biased as to effect. To offset this, we used independent evaluation by multiple physicians. Clearly, more work is needed to fully determine the efficacy of peramapnel in this syndrome and to elucidate the exact treatment paradigm to maximize outcomes.
Recently, a second function of ATAD1 was reported; it acts as part of a quality control system for the mitochondrial membrane. 19 It is unclear how this function may relate to the patients' phenotype; perampanel would not be expected to reverse deficits in this pathway.
Despite the clear benefits of this individualized medicine approach, there is likely an intrinsic limitation to the maximal benefit of perampanel therapy in patients with ATAD1 mutations. The high doses required in this disorder also inhibit the more subtle modulation of AMPA receptor activity that is crucial for normal CNS functioning. This limitation is supported by the fact that although perampanel prolongs survival and stops seizures in ATAD1 2/2 mice, they still die at a younger age as compared to their wildtype littermates.
Mice and humans with mutations in ATAD1, a mediator of AMPA receptor recycling, manifest with a devastating neurologic disorder that responds to targeted therapy with an FDA-approved AMPAreceptor blocker, perampanel. These first studies establish the promise of this approach, but further studies are needed to elucidate both the natural history and the therapeutic potential of perampanel in patients with ATAD1 mutations.
